American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

Felson, David T., Anderson, Jennifer J., Boers, Maarten, Bombardier, Claire, Furst, Daniel, Goldsmith, Charles, Katz, Linda M., Lightfoot, Robert, Paulus, Harold, Strand, Vibeke, Tugwell, Peter, Weinblatt, Michael, James Williams, H., Wolfe, Frederick, Kieszak, Stephanie·1995·Arthritis & Rheumatism

DOI 10.1002/art.1780380602

Open this paper in CoChat — free account

Abstract

Objective. Trials of rheumatoid arthritis (RA) treatments report the average response in multiple outcome measures for treated patients. It is more clinically relevant to test whether individual patients improve with treatment, and this identifies a single primary efficacy measure. Multiple definitions of improvement are currently in use in different trials. The goal of this study was to promulgate a single definition for use in RA trials. Methods. Using the American College of Rheumatology (ACR) core set of outcome measures for RA trials, we tested 40 different definitions of improvement, using a 3‐step process. First, we performed a survey of rheumatologists, using actual patient cases from trials, to evaluate which definitions corresponded best to rheumatologists' impressions of improvement, eliminating most candidate definitions of improvement. Second, we tested 20 remaining definitions to determine which maximally discriminated effective treatment from placebo treatment and also minimized placebo response rates. With 8 candidate definitions of improvement remaining, we tested to see which were easiest to use and were best in accord with rheumatologists' impressions of improvement. Results. The following definition of improvement was selected: 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acutephase reactant. Additional validation of this definition was carried out in a comparative trial, and the results suggest that the definition is statistically powerful and does not identify a large percentage of placebo‐treated patients as being improved. Conclusion. We present a definition of improvement which we hope will be used widely in RA trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/art.1780380602

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Self-citation
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
Maini, R. N., Taylor, P. C., Szechinski, J., Pavelka, K., Bröll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22033 · Cited by 790
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: Results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trial
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638
Self-citation
Exercises for mechanical neck disorders
Gross, A., Kay, T. M., Paquin, J.-P., Blanchette, S., Lalonde, P., Christie, T., Dupont, G., Graham, N., Burnie, S. J., Gelley, G., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004250.pub5 · Cited by 613
Self-citation
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial
Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526
Manual therapy and exercise for neck pain: A systematic review
Miller, J., Gross, A., D'Sylva, J., Burnie, S. J., Goldsmith, C. H., Graham, N., Haines, T., Brønfort, G., & Hoving, J. L. (2010) · Manual Therapy · doi:10.1016/j.math.2010.02.007 · Cited by 393
Self-citation
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Burmester, G. R., Kremer, J. M., Van den Bosch, F., Kivitz, A., Bessette, L., Li, Y., Zhou, Y., Othman, A. A., Pangan, A. L., & Camp, H. S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31115-2 · Cited by 373
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
Greenberg, J. D., Kremer, J. M., Curtis, J. R., Hochberg, M. C., Reed, G., Tsao, P., Farkouh, M. E., Nasir, A., Setoguchi, S., & Solomon, D. H. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.129916 · Cited by 350
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202646 · Cited by 343
Sex differences in rheumatoid arthritis: more than meets the eye
van Vollenhoven, R. F. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-12 · Cited by 326
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study
Genovese, M. C., Fleischmann, R., Kivitz, A. J., Rell‐Bakalarska, M., Martincova, R., Fiore, S., Rohane, P., van Hoogstraten, H., Garg, A., Fan, C., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39093 · Cited by 219
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
Aletaha, D., Landewe, R., Karonitsch, T., Bathon, J., Boers, M., Bombardier, C., Bombardieri, S., Choi, H., Combe, B., Dougados, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.24123 · Cited by 214
Self-citation
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors
Genovese, M. C., Greenwald, M., Cho, C., Berman, A., Jin, L., Cameron, G. S., Benichou, O., Xie, L., Braun, D., Berclaz, P., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38617 · Cited by 211
Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis
Tseng, S., Reddi, A. H., & Di Cesare, P. E. (2009) · Biomarker Insights · doi:10.4137/bmi.s645 · Cited by 204
Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon‐Campos, J. A., Porawska, W., Box, J., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30463 · Cited by 196
Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review
Cook, J., Hislop, J., Adewuyi, T., Harrild, K., Altman, D., Ramsay, C., Fraser, C., Buckley, B., Fayers, P., Harvey, I., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18280 · Cited by 194
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study
Blanco, F. J., Möricke, R., Dokoupilova, E., Codding, C., Neal, J., Andersson, M., Rohrer, S., & Richards, H. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40070 · Cited by 185
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Fleischmann, R., van Adelsberg, J., Lin, Y., Castelar‐Pinheiro, G. D. R., Brzezicki, J., Hrycaj, P., Graham, N. M. H., van Hoogstraten, H., Bauer, D., & Burmester, G. R. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39944 · Cited by 178
The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases
Aletaha, D., & Smolen, J. S. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.09.005 · Cited by 152
An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial
Pincus, T., Strand, V., Koch, G., Amara, I., Crawford, B., Wolfe, F., Cohen, S., & Felson, D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10824 · Cited by 146
Self-citation
Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
Ogata, A., Tanimura, K., Sugimoto, T., Inoue, H., Urata, Y., Matsubara, T., Kondo, M., Ueki, Y., Iwahashi, M., Tohma, S., et al. (2014) · Arthritis Care & Research · doi:10.1002/acr.22110 · Cited by 140
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
Smolen, J. S., Weinblatt, M. E., Sheng, S., Zhuang, Y., & Hsu, B. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205137 · Cited by 139
Self-citation
Leflunomide: A Review of its Use in Active Rheumatoid Arthritis
Prakash, A., & Jarvis, B. (1999) · Drugs · doi:10.2165/00003495-199958060-00010 · Cited by 135
The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
Jobanputra, P., Barton, P., Bryan, S., & Burls, A. (2002) · Health Technology Assessment · doi:10.3310/hta6210 · Cited by 126
Exogenous and endogenous glucocorticoids in rheumatic diseases
Buttgereit, F., Burmester, G., Straub, R. H., Seibel, M. J., & Zhou, H. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30070 · Cited by 105
The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study
Weinblatt, M. E., Mease, P., Mysler, E., Takeuchi, T., Drescher, E., Berman, A., Xing, J., Zilberstein, M., Banerjee, S., & Emery, P. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39249 · Cited by 98
Self-citation
Ottawa panel evidence-based clinical practice guidelines on therapeutic massage for neck pain
Brosseau, L., Wells, G. A., Tugwell, P., Casimiro, L., Novikov, M., Loew, L., Sredic, D., Clément, S., Gravelle, A., Hua, K., et al. (2012) · Journal of Bodywork and Movement Therapies · doi:10.1016/j.jbmt.2012.04.001 · Cited by 89
Self-citation
A tailored-guided internet-based cognitive-behavioral intervention for patients with rheumatoid arthritis as an adjunct to standard rheumatological care: results of a randomized controlled trial
Ferwerda, M., van Beugen, S., van Middendorp, H., Spillekom-van Koulil, S., Donders, A. R. T., Visser, H., Taal, E., Creemers, M. C. W., van Riel, P. C. L. M., & Evers, A. W. M. (2017) · Pain · doi:10.1097/j.pain.0000000000000845 · Cited by 85
A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS)
Wessels, A. M., Siemers, E. R., Yu, P., Andersen, S. W., Holdridge, K. C., Sims, J. R., Sundell, K., Stern, Y., Rentz, D. M., Dubois, B., et al. (2015) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2015.82 · Cited by 86
A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate
Pavelka, K., Chon, Y., Newmark, R., Lin, S.-L., Baumgartner, S., & Erondu, N. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141271 · Cited by 83
Double-Blind, Randomized, Controlled, Pilot Study Comparing Classic Ayurvedic Medicine, Methotrexate, and Their Combination in Rheumatoid Arthritis
Furst, D. E., Venkatraman, M. M., McGann, M., Manohar, P. R., Booth-LaForce, C., Sarin, R., Sekar, P. G., Raveendran, K. G., Mahapatra, A., Gopinath, J., et al. (2011) · JCR: Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31821c0310 · Cited by 79
Patient‐reported outcome II: selecting appropriate measures for musculoskeletal care
Haywood, K. L. (2007) · Musculoskeletal Care · doi:10.1002/msc.101 · Cited by 30
Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy.
Song, R., Choi, H. M., Yang, H.-I., Yoo, M. C., Park, Y.-B., & Kim, K. S. (2012) · Clinical Rheumatology · doi:10.1007/s10067-012-2011-7 · Cited by 7

Authors: Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., Tugwell, P., Weinblatt, M., James Williams, H., Wolfe, F., & Kieszak, S.
Venue: Arthritis & Rheumatism
Publisher: Wiley
Published: 1995-06
Volume: 38
Issue: 6
Pages: 727-735
ISSN: 0004-3591 (ISSN-L)
1529-0131
DOI: 10.1002/art.1780380602
OpenAlex: W2159106700
Cited by: 2,829
References: 0
FWCI: 19.13
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cited by

Metadata

Record

About these checks

Data sources